Welcome to our dedicated page for Aptevo Therapeutics news (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics stock.
Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company developing bispecific and trispecific immunotherapies for cancer, and its news flow reflects both scientific progress and capital markets activity. On this APVO news page, readers can follow company-issued updates and third-party coverage related to its immune-oncology pipeline and corporate developments.
Aptevo’s recent press releases highlight key milestones for mipletamig, its CD123 x CD3 T-cell engager in the RAINIER Phase 1b/2 trial for frontline acute myeloid leukemia. News items include reports of remission rates in early cohorts, safety observations such as the absence of cytokine release syndrome in frontline patients treated to date in reported cohorts, and presentations of data at major medical meetings like the American Society of Hematology (ASH).
Investors and clinicians can also track announcements on Aptevo’s expanding CD3-engaging portfolio, including bispecific candidates APVO442 (PSMA x CD3) for prostate cancer and APVO455 (Nectin-4 x CD3) for multiple solid tumor types, as well as trispecific candidates APVO451 and APVO452 that combine tumor targeting, T-cell activation, and CD40-mediated costimulation. News coverage often details preclinical data presented at scientific conferences such as the Society for Immunotherapy of Cancer (SITC).
In addition to R&D and clinical trial updates, APVO news includes quarterly financial results, descriptions of its cash runway, and disclosures about equity financings, including at-the-market offerings, registered direct offerings, and an equity line of credit structure. Regulatory and governance developments, such as reverse stock split implementation, Nasdaq compliance updates, and amendments to rights agreements, are also reported.
By reviewing the APVO news feed, readers can monitor how Aptevo communicates progress on its ADAPTIR and ADAPTIR-FLEX platform-derived candidates, its interactions with the capital markets, and its participation in scientific and industry conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aptevo Therapeutics reported significant 2022 milestones and financial results, achieving a net income of $8.0 million ($1.57 per share) compared to a net loss of $28.5 million in 2021. The company announced progress in clinical trials for APVO436 in Acute Myeloid Leukemia (AML), which demonstrated substantial clinical activity and a favorable safety profile. The Phase 2 trial for APVO436 is set for late 2023. Additionally, ALG.APV-527, for solid tumors, began patient dosing in February 2023. Aptevo also filed a provisional patent for APVO711 targeting various solid malignancies. As of December 31, 2022, cash and equivalents totaled $22.6 million.
Aptevo Therapeutics (NASDAQ:APVO) announced the completion of a transaction that raised $9.6 million in non-dilutive funding by selling future IXINITY payments and milestones to XOMA Corporation. The company plans to use part of the proceeds to fully repay its debt, leaving it with approximately $26 million in cash and a debt-free status. Additional potential milestones related to IXINITY could yield up to $5.8 million through regulatory approvals and sales performance. This move extends Aptevo's cash runway beyond 12 months and reinforces its commitment to shareholders amid challenging market conditions.